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Global gene expression analysis was performed on a panel of 23 osteosarcoma samples of primary and metastatic origin
using the Applied Biosystems Gene Expression Array System. When comparing the primary tumours with the metastases, we
found a signiﬁcantly increased expression of genes involved in immunological processes, for example coding for cytokines and
chemokines, in the metastatic samples. In addition, a comparison of the gene expression in primary samples from patients with
or without metastases demonstrated that patients who later developed metastases had high expression of the chemokine (C-X-C
motif) receptor 4 (CXCR4), similar to the metastatic samples, suggesting that these signal molecules play an important role in
promoting metastasis. Increased knowledge of mechanisms and interactions between speciﬁed molecular signalling pathways in
osteosarcomas could lead to a more rational strategy for development of targeted therapy.
1.Introduction
Osteosarcoma is the most frequent primary malignant tum-
our of bone in children and adolescents, with a peak inci-
dence at the age of 15–19 years, and has an annual incidence
of 4/million/year world-wide (reviewed in [1, 2]). Osteosar-
comas are rare, osteoid-producing malignant tumours that
usually arise in the metaphyseal regions of long bones, in
particular, the distal femur, proximal tibia, and proximal
humerus [2]. Although most osteosarcomas are diagnosed
without a predisposing condition, approximately 15% arise
in adults secondary to a predisposing genetic condition (Li-
Fraumenisyndrome,hereditaryretinoblastoma;RB),disease
(Paget disease of bone), or prior treatment (radiation) [2].
Most conventional osteosarcomas are high-grade tum-
ours with a complex karyotype that displays numerous
genetic aberrations [2]. Despite the advances in multimodal
treatment combining adjuvant chemotherapy and surgical-
wideresection,the5-yearsurvivalrateforpatientsdiagnosed
withosteosarcomawithoutpresenceofmetastasisremainsin
the order of 60–65% (reviewed in [3, 4]). Metastases are the
leading cause of cancer-related death, and around 13–27%
of the osteosarcoma patients have detectable metastases at
diagnosis [3–6], whereas 40% will develop metastases at a
later stage [4]. The metastatic process shows a tropism for
lungs (80%), with skeleton as the second most common site
[4]. The 5-year survival rate for osteosarcoma patients with
primary metastases is in the range of 20–29% [4, 7, 8].2 Sarcoma
Molecular pathways contributing to osteosarcoma devel-
opment and progression have recently been discovered
(reviewed in [9, 10]), and this may facilitate better diagnosis
and prognostication, as well as the development of new
treatment strategies. The molecular alterations contribut-
ing to metastasis in osteosarcomas are increasingly being
understood (reviewed in [4]), and several studies have
employed microarray gene expression proﬁling to identify
genes involved in the metastasis process. Comparisons of
high- and low-metastatic osteosarcoma cell lines using
microarrays have identiﬁed several diﬀerentially expressed
genes related to growth arrest and apoptosis [11], as well as
adherence, motility, and/or invasiveness [12]. Another study
identiﬁed two genes not previously linked to osteosarcoma,
epiregulin (EREG) and carbohydrate (N-acetylglucosamine-
6-O)sulfotransferase2(CHST2),bothpredictiveforsurvival
[13]. A recent gene expression proﬁling of osteosarcoma
patients who did and did not develop metastasis revealed a
number of diﬀerentially expressed genes related to immuno-
logical functions, particularly macrophages [14].
Due to the high incidence of metastasis and low survival
rate in metastatic osteosarcoma patients, we wanted to
investigatethediﬀerencesingeneexpressionpatternbetween
primary and metastatic tumours. Microarray gene expres-
sion analysis was performed on a panel of 23 osteosarcoma
samples of primary and metastatic origin, and the expres-
sion patterns were compared in order to identify diﬀer-
entially expressed genes and molecular signalling pathways
involved.
2.MaterialsandMethods
2.1. Biological Material. Twenty-three human osteosarcomas
were selected from a tumour panel at the Department
of Tumour Biology at the Norwegian Radium Hospital,
collected during two decades (1983–2004). Clinical samples
were collected immediately after surgery, cut into small
pieces, frozen in liquid nitrogen, and stored at −80◦C
until use. The informed consent used and the collection
of samples were approved by the Ethical Committee of
Southern Norway (Project S-06133).
All tumours were revised at the time of the study
by the pathologist (BB) and diagnosed according to the
current World Health Organization classiﬁcation [2]. The
clinical information was retrieved anonymously from the
MEDinsight database at the Norwegian Radium Hospital
(http://medinfo.net/medinsight/). The panel consisted of 12
primary tumours obtained from open biopsies or surgical
specimensand11tumoursobtainedfromsurgicalspecimens
of distant metastases. Of the 12 primary tumours, 7 were
from patients who later developed metastases and 4 from
those who did not (clinical information about the metastatic
process was not available for one primary tumour). The
follow-up of the patients who did not develop metastasis
was in the range 5–19 years. Median patient age was 18
(range 11–50), and the gender ratio (female:male) was
1:1.3. Clinical information on the tumour samples are given
in Table 1.
Two normal bone samples were included for the quan-
titative real-time RT-PCR experiments. Bone1 was collected
from the femur of a renal cell carcinoma patient and Bone2
from the tibia of an osteosarcoma patient. For both patients,
the normal samples were collected distant from the margin
of the tumours.
2.2. Microarray Experiments. The microarray experiments
were performed with the Applied Biosystems Gene Ex-
pression Array System, and the samples were hybridised
on the Human Genome Survey Microarray V2.0 (Applied
Biosystems, Foster City, CA, USA) with 32k probes covering
29k genes. The complete dataset can be viewed in the Gene
Expression Omnibus (GEO) microarray database (http://
www.ncbi.nlm.nih.gov/geo/, accession number GSE32981).
2.3. RNA Isolation and Hybridization. RNA was extracted
by TRIzol (OS3, 4, 12, 18, 21, 41, 47, 48, 50, 51, 53, 55)
or GTC (OS11, 14, 15, 17, 19, 20, 23, 25, 29, 30, and
32) using standard protocols. RNA purity and quantity
weremeasuredonaNanoDropND-1000spectrophotometer
(Nanodrop Technologies, Wilmington, DE, USA), and RNA
integrity was evaluated on an Agilent 2100 Bioanalyzer
(Agilent Technologies Inc., Santa Clara, CA, USA) using
the total-RNA chip. The RNA was ampliﬁed, hybridised
on the Human Genome Survey Microarray V2.0 (Applied
Biosystems), and scanned according to the manufacturer’s
protocols.
2.4. Preprocessing and Filtering. The microarray image ﬁles
were pre-processed with the AB1700 software (Applied
Biosystems) and the resulting data ﬁles were stored in
BASE [15]. The data were further processed with the R
package ABarray, which is part of the Bioconductor project
(http://www.R-project.org/)[ 16]. The data were quantile
normalized, log2 transformed, and missing values were
imputed using average values from the other arrays in the
subgroup. The osteosarcoma samples were divided into two
groups of primary or metastatic origin. Weakly expressed
probes were ﬁltered away by deﬁning that a probe is only
detected if it has a signal-to-noise ratio (SNR) ≥ 3i na tl e a s t
50%ofthesamplesineithersubgroupprimaryormetastatic.
2.5. Data Analysis. Using the database Panther [17, 18], a
Wilcoxon Rank-Sum test was performed to identify enriched
biological pathways using all of the genes that were expressed
above the detection limit and mapped to Celera ID.
The data were imported to J-Express 2.7 [19], and the
values were merged to gene level using the max probe
function. The Statistical Analysis of Microarrays (SAM)
plug-in [20] was used to identify diﬀerentially expressed
genes between the primary and the metastatic samples,
as well as between the primary samples that did and
did not develop into metastases. Signiﬁcant genes were
identiﬁed using the d-value, which measures the strength of
the relationship between gene expression and the response
variable. An analysis was performed on the discriminatory
genelistswherethegeneswerecategorizedbasedonenrichedSarcoma 3
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Table 2: Enriched Panther pathways in the metastases compared to the primary tumours. The ﬁve most signiﬁcant pathways are shown with
the number of genes in the pathways. + or − signs indicate that for the genes belonging to this pathway, the distribution of fold change values
is shifted towards higher or lower values, respectively, than the overall distribution of all genes that were uploaded. P-values were calculated
from the Wilcoxon Rank-Sum test and Bonferroni corrected for multiple testing.
Pathways # Genes +/− P-value
T cell activation 134 + 5.5E–14
Inﬂammation mediated by chemokine and cytokine signaling pathway 299 + 2.1E–11
B cell activation 92 + 7.2E–7
EGF receptor signaling pathway 175 + 1.0E–3
Integrin signaling pathway 244 + 1.8E–3
Gene Ontology (GO) processes using Panther. Hierarchical
clustering was done in J-Express, and the gene expression is
given relative to the mean expression level in all the samples.
2.6. Quantitative Real-Time RT-PCR. Quantitative real-time
RT-PCR was performed using TaqMan Gene Expression
Assays (Applied Biosystems, California, USA). The expres-
sion level of the gene chemokine (C-X-C motif) receptor 4
(CXCR4, assay ID Hs00237052 m 1 )w a sd e t e r m i n e di n1 9o f
the tumour samples and 2 normal bone samples. The genes
beta-2-microglobulin (B2M, assay ID Hs99999907 m1),
TATA-box binding protein (TBP, assay ID Hs99999910 m1),
and eukaryotic 18S rRNA (18S, assay ID Hs99999901 s1)
were used as endogenous controls for normalization. Uni-
versal Human Reference RNA (Stratagene, California, USA)
was used as a reference.
TheHighCapacitycDNAArchiveKit(LifeTechnologies)
was used to synthesize cDNA, and real-time PCR was
performed using the ABI 7500 Real Time PCR System and
software, essentially as described in the protocol supplied by
the manufacturer (Applied Biosystems). Each assay included
(in duplicate) a standard curve of six serial dilutions of
the Universal Human Reference RNA cDNA (ranging from
100ng to 100pg), 10ng of each tumour and normal bone
cDNA,andano-templatecontrol.Theexpressionlevelswere
determined from the standard curves as described by the
manufacturer. The expression level of CXCR4 was normal-
ized with the average expression of the three endogenous
controls, and the relative expression of the tumour samples
was compared to the average expression of the two normal
bone samples.
3. Results
3.1. Comparison of Primary and Metastatic Tumours. Gene
expression proﬁling was performed on a panel of 23 human
osteosarcoma samples of primary and metastatic origin.
The clinical information on the tumour samples is given in
Table 1.Twelveprimaryand11metastaticsampleswereanal-
ysed to identify diﬀerences in gene expression and pathways
with enrichment of diﬀerentially expressed genes between
the two groups. After SNR ﬁltering, 22,510 genes were
expressed above the detection limit, of which 21,378 had
Celera IDs. Unsupervised hierarchical clustering of all the
samples revealed no speciﬁc patterns, and the primary and
metastatic samples clustered intermingled (data not shown).
The analysis using Panther identiﬁed several pathways with
enriched diﬀerential expression between the primary and
metastatic samples, and these are listed in Table 2.T h e
genes in the pathway were generally higher expressed in the
metastasesthanintheprimarysamples.Themostprominent
pathways are involved in immunological processes and
chemokine and cytokine signalling, as well as pathways like
the EGF receptor signalling pathway, including genes coding
for the FBJ murine osteosarcoma viral oncogene homolog
(FOS), early growth response 1 and -2 (EGR1 and -2).
The primary and metastatic samples were further com-
pared by SAM analysis in order to identify the most diﬀeren-
tially expressed genes separating these two groups, and the
top-210 gene list based on the d-value is given in Supple-
mentary Table 1 available at doi:10.1155/2012/639038. The
majority of these genes were upregulated in the metastases
compared to the primary tumours. Figure 1 shows the
hierarchical clustering of all the tumours based on the
expression pattern of these 210 genes (the same ﬁgure
with the gene names indicated is given in Supplementary
Figure 1). The samples were separated into two main
clusters, one consisting of all primary and a subset of the
metastatic samples and one with only metastatic samples.
Among the primary samples, there was one subcluster that
strongly diverged from the other samples, consisting of three
samples that did not metastasize and the one sample with
unknown metastatic status. Among the genes separating
the metastatic samples into diﬀerent subclusters, a high
number of surfactants were present, being highly expressed
in all the samples of the subcluster that only contained lung
metastases. In addition, several interesting clusters of genes
were observed to be upregulated in both of the metastatic
subclusters, like the group consisting of chemokine (C-X-
C motif) ligand 1, -2, and -3 (CXCL1,- 2,a n d- 3)a n d
interleukin 6 (interferon, beta 2) (IL6), as well as the group
consisting of EGR1,- 2, FOSB, FOS, and jun B proto-
oncogene (JUNB), both highlighted (blue and green colour,
resp.) in Figure 1.
To further explore the function of these 210 diﬀerentially
expressed genes, they were classiﬁed into Gene Ontology
(GO) Biological process and Molecular function, listed in
Table 3. Interestingly, there was a signiﬁcant overrepresenta-
tion of genes involved in immunity and defence, especially
cytokines and chemokines like CXCL1,- 2,- 3,- 5, IL1B,- 6,
-8,- 17D and oncostatin M (OSM). These signal molecules
have a higher expression in metastatic samples comparedSarcoma 5
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Figure 1: Hierarchical clustering of all tumours based on the top-210 signiﬁcant genes diﬀerentially expressed between metastases and
primary tumours, identiﬁed by SAM analysis. Samples coloured in red, metastases; lilac, primary samples from patients who later developed
metastases; green, primary samples from patients who did not develop metastases blue, clinical information on metastases not available.
Gene cluster coloured in blue, CXCL1, -2,- 3, IL6, and LOC131873;g r e e n ,EGR1,- 2, FOSB, FOS, and JUNB; red, surfactant genes. Red,
increased gene expression; green, decreased gene expression. The cluster was made using average linkage and Pearson’s correlation.6 Sarcoma
Table 3: GO groups with signiﬁcant enrichment, based on a comparison of the top-210 signiﬁcant genes diﬀerentially expressed between
metastasesandprimarytumoursagainstallgenespresentonthemicroarray.Thenumberofgenesinthetotallistandobservedandexpected
number of genes in the gene list that map to the GO group are shown. + or − signs indicate over- or underrepresentation, respectively, of
this GO group. P-values were Bonferroni corrected for multiple testing, P-value < 0.05.
GO group # Genes total
Gene list
#O b s e r v e d #E x p e c t e d + / − P-value
Biological process
Immunity and defence 1365 30 11.3 + 3.7E–5
Granulocyte mediated immunity 59 6 0.5 + 1.7E–3
Macrophage mediated immunity 126 8 1.1 + 1.8E–3
Cell proliferation and diﬀerentiation 944 20 7.8 + 4.2E–3
Blood circulation and gas exchange 82 5 0.7 + 2.0E–2
Cell cycle control 390 12 3.2 + 1.7E–2
JNK cascade 60 5 0.5 + 3.2E–2
Molecular function
Surfactant 9 5 0.7 + 2.8E–6
Chemokine 45 5 0.4 + 6.8E–3
Interleukin 34 4 0.3 + 4.1E–2
with primary samples, and the high expression level seems to
be strongly associated with metastasis. In addition, a group
of surfactants, surfactant protein A1, -A2, -B, -C, and -D
(SFTPA1,- A2,- B,- C, and -D) was observed to be higher
expressed in a subset of the metastatic samples, contributing
to a gene cluster that distinguished between lung and non-
lung metastases (coloured red in Figure 1).
3.2. Comparison of Primary Tumours with Diﬀerent Capabil-
ity to Metastasize. To further look into the genes apparently
involved in the metastatic process, the primary samples from
the patients who developed metastases were compared with
those who did not. A SAM analysis of seven primary samples
that metastasized and four that did not resulted in a short list
of genes that were diﬀerentially expressed between the two
groups of primary samples. The top-20 gene list based on the
d-value is shown in Table 4. Figure 2 shows the hierarchical
clustering of the primary samples based on the expression
of these 20 genes. The primary samples that developed into
metastases clustered separately from the primary samples
that did not. Thirteen of the diﬀerentially expressed genes
were upregulated in the primary samples that developed
into metastases, whereas seven genes were downregulated.
Among the genes that were upregulated in the primary
samples from patients who later developed metastases was
the chemokine (C-X-C motif) receptor 4 (CXCR4), known
to be involved in the metastatic process.
Figure 3(a) shows the expression level of the CXCR4
gene in all the samples. CXCR4 was expressed at the same
level in metastatic samples and in primary samples that
developed metastases, with a signiﬁcantly lower expression
level in primary samples that did not metastasize compared
to the two other groups (P<0.001 for both comparisons).
The expression was also signiﬁcantly diﬀerent between all
the primary samples combined and the metastatic samples
(P<0.05). The expression level was also determined in
19 of the tumour samples compared to two normal bone
samples using quantitative real-time RT-PCR, and this is
shown in Figure 3(b). The relative expression levels were
in general similar using the two methods, with higher
expression of CXCR4 in the primary samples that developed
metastasesandthemetastaticsamples.Mostsamplesshowed
similar expression levels, only OS14 was markedly diﬀerent.
However,thereweresmallerrelativediﬀerencesinexpression
level between the samples based on the quantitative real-
time RT-PCR data, and the expression was not signiﬁcantly
diﬀerent between the groups here.
4. Discussion
Osteosarcomas show complex genomic changes with few,
if any, consistent chromosomal aberrations, which makes
it diﬃcult to identify the molecular features that underlie
the development of this type of cancer. The aim of this
study was to investigate the diﬀerences in gene expression
pattern between primary and metastatic tumours, and a
number of pathways and genes with diﬀerential expression
were identiﬁed (Tables 2 and 3 and Figure 1). In general,
the genes were more highly expressed in the metastases
than in the primary osteosarcoma tumour samples. Of
particular interest, we identiﬁed a number of immunological
processes, including the T cell and B cell activation, as well
aschemokineandcytokinesignallingpathways.Chemokines
are chemotactic cytokines, a family of small cytokines or
proteins secreted by cells, and the major role of chemokines
is to control and direct the migration of cells. It has been
increasingly known that chemokines play an important part
in regulation of the metastatic cascade in a wide range of
tumours, including osteosarcomas [21–24]. Tumour cells
that are attracted by chemokines have an increased expres-
sion of particular chemokine receptors on their surface.
The cells migrate towards a signal of increasing chemokineSarcoma 7
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Figure 2: Hierarchical clustering of all primary tumours based on the top-20 signiﬁcant genes diﬀerentially expressed between primary
samples from patients who developed metastases and those who did not, identiﬁed by SAM analysis (one primary tumour with no clinical
information on metastases was excluded). Samples coloured in lilac, primary samples from patients who later developed metastases; green,
primarysamplesfrompatientswhodidnotdevelopmetastases.Red,increasedgeneexpression;green,decreasedgeneexpression.Thecluster
was made using average linkage and Pearson’s correlation.
concentration provided by the source of the chemokine,
and this process enables them to migrate to secondary
tissues where chemokine ligands are highly expressed. Part
of the identiﬁed diﬀerences between primary and metastatic
samples could be due to the origin of the samples, although
the histology of primary and pulmonary metastatic osteosar-
coma samples has been reported to be similar in about 60%
of the cases [25, 26].
The chemokines CXCL1,- 2,- 3,- 5, and IL8 (CXCL8)
were among the top-210 genes that were observed to be8 Sarcoma
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Figure 3: Relative CXCR4 expression in primary tumours from patients who did or did not develop metastases and in metastatic samples
(one primary tumour with no clinical information on metastases was excluded) based on (a) microarray data and (b) quantitative real-time
RT-PCR data. For the quantitative real-time RT-PCR data, the expression levels have been normalised to the average expression of three
housekeeping genes (18S, B2M and TBP) and compared to the average expression of two normal bone samples. The average expression level
in each sample group is indicated with a black bar. NA, not available.
upregulated in metastases compared with primary tumours,
and they showed highly correlated expression patterns
(Figure 1,SupplementaryTable1,andSupplementaryFigure
1). This is similar to previous observations in breast cancer
tumours and cell lines, where these chemokines have been
suggested to account for a higher aggressiveness of ERα-
positive tumours [27]. These genes are located in the 4q21
region, and although the gene cluster was not ampliﬁed
in breast cancer, it was observed to be coregulated at the
transcriptional level. Regions in 4q have been shown to
have increased copy number in osteosarcomas [28, 29],
but ampliﬁcation of the 4q21 region has not recurrently
been reported. In breast cancer, CXCL8 expression level
strongly correlated with activating transcription factor 3
(ATF3), c-Jun and JunB, members of the AP-1 transcription
factor complex [27], and ATF3 and JunB were also observed
to be upregulated in the metastatic osteosarcoma samples
investigated here.
Several other chemokines were upregulated in the
metastatic osteosarcomas, including OSM, which has been
claimed to have both pro-inﬂammatory and anti-inﬂamma-
tory eﬀects. OSM has been shown to induce bone loss andSarcoma 9
Table 4: Top-20 genes identiﬁed by SAM analysis as diﬀerentially expressed in the comparison of primary samples from patients who
developed metastases and those who did not.
Gene symbol Gene name Fold change d-value
CXCR4 Chemokine (C-X-C motif) receptor 4 3.1 4.3
LOC339903 — −8.6 −3.7
TMEM37 Transmembrane protein 37 3.1 3.6
MAP3K15 Mitogen-activated protein kinase kinase kinase 15 4.1 3.4
BFSP1 Beaded ﬁlament structural protein 1, ﬁlensin 5.1 3.4
DKFZp586C0721 — 3.2 3.4
hCG1820791 — 2.7 3.3
IRX2 Iroquois homeobox protein 2 9.2 3.3
NLGN4Y Neuroligin 4, Y-linked −6.9 −3.3
C1QTNF7 C1q and tumor necrosis factor related protein 7 −12.5 −3.2
ARHGAP28 Rho GTPase activating protein 28 −6.7 −3.2
PRKAR2B Protein kinase, cAMP-dependent, regulatory, type II, beta 6.8 3.2
RAPGEF4 Rap guanine nucleotide exchange factor (GEF) 4 4.1 3.2
LOC441340 — 4.1 3.2
RGS4 Regulator of G-protein signalling 4 5.8 3.1
ZNF396 Zinc ﬁnger protein 396 −2.4 −3.1
PRSS27 Protease, serine 27 −1.8 −3.1
USMG5 Upregulated during skeletal muscle growth 5 −5.9 −3.0
LENG1 Leukocyte receptor cluster (LRC) member 1 2.5 3.0
ARHGEF16 Rho guanine exchange factor (GEF) 16 4.9 3.0
sensitized rat osteosarcoma to apoptosis [30] and induce
diﬀerentiation of chondrosarcoma and osteosarcoma cells
[31, 32]. However, several studies show that OSM may
enhance tumour progression and metastasis. Stimulation
of human and canine osteosarcoma cells by OSM has
been shown to promote invasive behaviour through acti-
vation of signal transducer and activator of transcription
3 (acute-phase response factor, STAT3) [33], and OSM
treatment increased migration and enhanced epithelial-to-
mesenchymal transition in several tumours [34–36].
Thehierarchicalclusteringbasedonthetop-210diﬀeren-
tially expressed genes separated the metastatic samples into
two subclusters (Figure 1). The smaller metastatic cluster,
which was more similar to the primary samples, consisted of
one pulmonary, one skeletal, and two samples that formed
multiple metastases of both the lungs and skeleton. The
majorclusterofmetastaticsamplesonlyincludedpulmonary
metastases, and these samples showed high expression of
surfactants. SP-A, SP-B, SP-C, and SP-D are expressed by
type II alveolar epithelia or Clara cells, assumed to be pro-
genitorsofpulmonaryadenocarcinomas,andhavebeenused
as markers of metastatic and micrometastatic pulmonary
adenocarcinoma and nonsmall cell lung carcinomas [37]. It
seems likely that the detection of these surfactants may be
due to contamination of lung tissue in the tumour samples,
although it is also possible that the lung microenvironment
induces these genes in the osteosarcoma cancer cells.
Interestingly, in the comparison of primary tumours
withdiﬀerentcapability tometastasize,primary samples that
did not metastasize showed signiﬁcantly lower expression
of the chemokine receptor CXCR4 than primary samples
from patients who later developed metastases (P<0.001)
(Table 4 and Figures 2 and 3(a)). The expression level was
similar between the primary samples that metastasized and
the metastatic samples. Although CXCR4 was not among the
top-rankedgenesfromtheSAManalysisofprimarytumours
and metastases, the expression level was signiﬁcantly dif-
ferent between all the primary tumours and the metastases
(P<0.05), most likely due to the lower level of expression in
theprimarysamplesthatdidnotmetastasize.Theexpression
level was also conﬁrmed using quantitative real-time RT-
PCR(Figure 3(b)),andalthoughthepatternsingeneralwere
similar between the two methods, no signiﬁcant diﬀerences
in expression were observed between the groups based on
this data.
Two of the metastatic samples, OS11 and OS18, origi-
nated from patients that did not develop metastases until 15
and 10 years after diagnosis, respectively. OS11 is a parosteal
osteosarcoma but expressed CXCR4 at the same level as the
other metastatic samples, while OS18 showed a low level of
CXCR4 expression. Both samples were untreated, in contrast
to the other metastatic samples, but the clustering analyses
showedthatthesetwocaseswerenotdiﬀerentfromtheother
metastatic samples, justifying the inclusion of these samples
in the study. Similarly, two primary samples were treated
(OS14 and OS19), in contrast to the other primary samples,
but these were also not diﬀerent from the other primary
samples. However, OS14 was the only samples showing
markedly diﬀerent expression level of CXCR4 depending on
the method used.
This study is the ﬁrst to use expression proﬁling to
identify that diﬀerential expression of CXCR4 separates10 Sarcoma
primary samples with diﬀerent capabilities to metastasize.
Although CXCR4 was not among the identiﬁed genes in a
recent publication by Buddingh et al. [14], the signiﬁcance
of CXCR4 in metastasis development in osteosarcoma and
other bone cancers has previously been reported. CXCR4 is
a speciﬁc receptor for the ligand SDF-1 (stromal-derived-
factor-1, also called CXCL12), and the CXCR4/CXCL12 axis
has been shown to be important for tumour progression
in a high number of cancer types [38]. In a mouse model,
the tumour cells with CXCR4 receptor were chemoattracted
by CXCL12, migrated through the lymphatic and vascu-
l a rs y s t e m ,a n da r r e s t e di nC X C L 1 2r i c ho r g a n sl i k et h e
bone and lungs [39]. Laverdiere et al. [24]o b s e r v e dn o
signiﬁcant diﬀerence between CXCR4 expression in primary
and metastatic samples, but the level of CXCR4 expression
was inversely correlated with the presence of metastases at
diagnosis and survival (event-free survival and metastatic-
free survival), as patients with tumors expressing CXCR4
had a worse survival. However, in a study by Oda et al.
[40], higher immunohistochemical CXCR4 expression was
observed in metastases compared with primary tumours.
Contradicting the above observation, a higher frequency
of canine osteosarcoma primary tumours than pulmonary
metastases expressed CXCR4 protein [41]. In an analysis
of Ewing sarcoma, another bone cancer, CXCR4 correlated
with metastases, and CXCR4 in combination with CXCR7
were shown to be prognostic indicators for patient survival
[23]. In chondrosarcoma of bone, CXCR4 showed higher
immunohistochemical staining in high-grade than in low-
grade samples, being a potential marker of aggressiveness
[42].
A note to make is that the RNA samples used in this
study were isolated using two diﬀerent methods, which may
inﬂuence the gene expression detected. The type of RNA
isolation was randomly distributed between the groups of
primary and metastatic samples, and with regard to other
clinical properties (Table 1). Although it cannot be ruled out
that the RNA isolation method has had an eﬀect on the
detected expression levels of CXCR4, the increasing evidence
of a role of CXCR4 in osteosarcoma metastasis makes us
believe that the expression diﬀerences observed here is due
to the sample types and not the RNA isolation methods.
Osteosarcoma consists of both tumour cells derived from
the mesenchyme as well as inﬁltrating mononuclear cells
[43], hence chemokines could be expressed both by tumour
c e l l sa sw e l la sb yt h es t r o m ac e l l si nt h e i rp r o x i m i t ya n da t
metastatic sites. Preliminary microarray results showed that
CXCR4andinterestingchemokineligandslikeCXCL1,-2,-3,
and -5 are only highly expressed in clinical samples and not
in xenografts or cell lines (Namløs et al., unpublished data),
a ﬁnding supported by a previous study of osteosarcoma
patient samples and cell lines [24]. This suggests that it
is inﬁltrating stroma (macrophages) and not the tumour
cells that is the major source of chemokine expression in
osteosarcoma, or possibly that only the human macrophages
are able to induce the expression of chemokines in the
tumour cells. However, Perissinotto et al. [39] detected the
CXCR4 receptor and a functional CXCR4/CXCL12 axis in
non-conﬂuent osteosarcoma cell lines. To further investigate
this, immunohistochemical staining should be performed
to examine the CXCR4 protein expression in the diﬀerent
cell types, which has previously been performed for other
chemokine receptors in osteosarcoma [44].
Inhibition of the CXCR4/CXCL12 pathway by a peptide
CXCR4 antagonist reduced the development of osteosar-
coma murine lung metastases [45]. In vivo studies on
breast cancer demonstrated that treatment with miRNA
or antibodies against CXCR4 impaired migration and the
development of murine lung metastases [21, 46]. This
indicates that small molecule antagonists against CXCR4 can
interfere with tumour progression and metastasis and may
potentially be used for new therapeutic inventions.
5. Conclusion
Although the number of samples analysed was moderate,
our results add to the increasing number of studies linking
CXCR4 to metastasis, suggesting that the expression level
of CXCR4 may possibly be used as a prognostic factor in
osteosarcoma. The identiﬁcation of chemokine pathways
that may promote cancer spread could give clinically useful
biomarkers for the prediction of particularly aggressive
tumours and might suggest therapeutic regimens that may
target such tumours.
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